The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Functional cure with earlier cilta-cel treatment in relapsed multiple myeloma
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses emerging evidence for functional cure in patients with relapsed multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel). He highlights the International Myeloma Society (IMS) definition of functional cure, incorporating sustained progression-free survival (PFS) without treatment, confirmed measurable residual disease (MRD) negativity and negative imaging, and notes increasing rates of patients meeting these criteria with earlier use of cilta-cel. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
